By Dawn MacNeill, Head of Supply Robustness
Every day, vaccines and drugs essential to the health of our global population are developed and manufactured in facilities around the world. These facilities are supported by a robust network of global and local supply chains through which essential raw materials and consumables transit.
The global COVID-19 pandemic has created a perfect storm of unprecedented demand for raw materials and consumables, such as Mobius® single-use assemblies, plus reduced capacity and throughput of production facilities due to the need for social distancing of employees.
In early 2020, at the outset of the pandemic, our business established three key principles which would support our ability to be agile as we based our decisions and prioritization off of the below critical areas:
- Employee Safety: ensure the safety and well-being of our employees and their families
- Public health: play a positive role in supporting public health
- Business Continuity: sustain our business well beyond the crisis
This white paper provides an overview of the short-, mid- and long-term strategies we have developed, implemented, and continue to advance in response to the pandemic. While this pandemic has truly been an upheaval of business and life for everyone around the world, our commitment to the biopharmaceutical industry and our employees remains firm.